InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（10 笔）
内部人交易记录
高级管理人员已披露买入
2
已披露卖出
10
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the detailed record of transactions filed by Sullivan Christopher Ryan, Directeur Comptable. Director active across 1 company, notably Avalo Therapeutics, Inc.. Cumulatively, 23 reports have been logged. Split: 2 buys · 10 sells. Total volume traded: €1.8m. History available since 10 December 2021. The latest transaction was filed on 10 September 2026 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Sullivan Christopher Ryan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报23 总计
10,185 股@ US$8.04Common StockSEC:0001810417-26-000021:0
10,185 股@ US$17.6197Common StockSEC:0001810417-26-000021:1
37,945 股@ US$9.880.036% mcap13.2% 占其流量Common StockSEC:0001810417-26-000019:0
2,876 股@ US$9.880.0027% mcap1.0% 占其流量Common StockSEC:0001810417-26-000019:1
37,945 股@ US$19.85330.072% mcap26.6% 占其流量Common StockSEC:0001810417-26-000019:2
3,749 股@ US$19.94190.0071% mcap2.6% 占其流量Common StockSEC:0001810417-26-000019:3
31,031 股@ US$9.880.029% mcap10.8% 占其流量Common StockSEC:0001810417-26-000019:4
31,031 股@ US$20.05490.059% mcap21.9% 占其流量Common StockSEC:0001810417-26-000019:5
138 股Common StockSEC:0001810417-26-000016:0
39,900 股0Common StockSEC:0001810417-26-000014:0
8,458 股@ US$13.09250.011% mcap27.0% 占其流量Common StockSEC:0001810417-26-000008:0
8,457 股@ US$13.22610.011% mcap27.2% 占其流量Common StockSEC:0001810417-26-000008:1
500 股@ US$15.8581.2% 占其流量Common StockSEC:0001810417-26-000006:0
7,479 股@ US$16.825918.6% 占其流量Common StockSEC:0001810417-26-000006:1
6,200 股@ US$17.024715.6% 占其流量Common StockSEC:0001810417-26-000006:2
1,780 股@ US$17.56744.6% 占其流量Common StockSEC:0001810417-26-000006:3
8,241 股@ US$13.890.011% mcap61.8% 占其流量Common StockSEC:0001810417-26-000004:1
24,200 股Common StockSEC:0001810417-26-000004:0
155 股@ US$4.100.1% 占其流量Common StockSEC:0001470831-25-000409:0
7,285 股@ US$8.4635.5% 占其流量Common StockSEC:0001578563-25-000198:1
24,200 股Common StockSEC:0001578563-25-000198:0
511 股@ US$3.421.0% 占其流量Common StockSEC:0001628280-23-021962:0
标准退出：2023年9月7日 (T+90)
955 股@ US$1.570.2% 占其流量Common StockSEC:0001879785-21-000039:0
标准退出：2022年3月10日 (T+90)
23 条申报中的 23 条
About Sullivan Christopher Ryan
Sullivan Christopher Ryan is Directeur Comptable and Chief Financial Officer at Avalo Therapeutics, Inc. The record shows 15 filings in total, and across the sampled recent filings from 2021-12-14 to 2026-06-12, buys amount to EUR 2948 and sells to EUR 424093, with the dominant transaction nature indicated as sale.
